4.7 Article

Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients

期刊

CLINICAL CANCER RESEARCH
卷 22, 期 1, 页码 69-78

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1078-0432.CCR-15-1344

关键词

-

类别

资金

  1. NCI [5U24-CA076518]
  2. NHLBI [5U10HL069294]
  3. National Institute of Allergy and Infectious Diseases (NIAID)
  4. Health Resources and Services Administration (HRSA/DHHS) [HHSH250201200016C]
  5. Office of Naval Research [N00014-13-1-0039, N00014-14-1-0028]
  6. Actinium Pharmaceuticals
  7. Allos Therapeutics, Inc.
  8. Amgen, Inc.
  9. Ariad
  10. Be the Match Foundation
  11. Blue Cross and Blue Shield Association
  12. Celgene Corporation
  13. Chimerix, Inc.
  14. Fred Hutchinson Cancer Research Center
  15. Fresenius-Biotech North America, Inc.
  16. Gamida Cell Teva Joint Venture Ltd.
  17. Genentech, Inc.
  18. Gentium SpA
  19. Genzyme Corporation
  20. Gilead Sciences, Inc.
  21. GlaxoSmithKline
  22. Health Research, Inc. Roswell Park Cancer Institute
  23. HistoGenetics, Inc.
  24. Incyte Corporation
  25. Jeff Gordon Children's Foundation
  26. Kiadis Pharma
  27. The Leukemia & Lymphoma Society
  28. Medac GmbH
  29. Medical College of Wisconsin
  30. Merck Co, Inc.
  31. Mesoblast
  32. Millennium: The Takeda Oncology Co.
  33. Milliman USA, Inc.
  34. Miltenyi Biotec, Inc.
  35. National Marrow Donor Program
  36. Neovii Biotech NA, Inc.
  37. Novartis Pharmaceuticals Corporation
  38. Onyx Pharmaceuticals
  39. Optum Healthcare Solutions, Inc.
  40. Osiris Therapeutics, Inc.
  41. Otsuka America Pharmaceutical, Inc.
  42. Perkin Elmer, Inc.
  43. Remedy Informatics
  44. Sanofi US
  45. Seattle Genetics
  46. Sigma-Tau Pharmaceuticals
  47. Soligenix, Inc.
  48. Spectrum Pharmaceuticals, Inc.
  49. St. Baldrick's Foundation
  50. StemCyte, A Global Cord Blood Therapeutics Co.
  51. Stemsoft Software, Inc.
  52. Strakan, Inc.
  53. Sunesis Pharmaceuticals, Inc.
  54. Swedish Orphan Biovitrum
  55. Tarix Pharmaceuticals
  56. TerumoBCT
  57. Teva Neuroscience, Inc.
  58. THERAKOS, Inc.
  59. University of Minnesota
  60. Wellpoint, Inc.
  61. Medical College of Wisconsin Institutional Research Grant from American Cancer Society [86-004-26]
  62. USC/UCLA Center on Biodemography and Population Health [NIA P30 AG017265]

向作者/读者索取更多资源

Purpose: Low socioeconomic status (SES) is associated with adverse outcomes among unrelated donor hematopoietic stem cell transplant (HCT) recipients, but the biologic mechanisms contributing to this health disparity are poorly understood. Therefore, we examined whether social environment affects expression of a stress-related gene expression profile known as the conserved transcriptional response to adversity (CTRA), which involves upregulation of proinflammatory genes and downregulation of genes involved in type I IFN response and antibody synthesis. Experimental Design: We compared pretransplant leukocyte CTRA gene expression between a group of 78 high versus low SES recipients of unrelated donor HCT for acute myelogenous leukemia in first remission. Post hoc exploratory analyses also evaluated whether CTRA gene expression was associated with poor clinical outcomes. Results: Peripheral blood mononuclear cells collected pre-HCT from low SES individuals demonstrated significant CTRA upregulation compared with matched HCT recipients of high SES. Promoter-based bioinformatics implicated distinct patterns of transcription factor activity, including increased CREB signaling and decreased IRF and GR signaling. High expression of the CTRA gene profile was also associated with increased relapse risk and decreased leukemia-free survival. Conclusions: Low SES is associated with increased expression of the CTRA gene profile, and CTRA gene expression is associated with adverse HCT clinical outcomes. These findings provide a biologic framework within which to understand how social environmental conditions may influence immune function and clinical outcomes in allogeneic HCT. (C)2015 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据